Research programme: anticancer monoclonal antibodies - Amgen
Latest Information Update: 21 Mar 2007
At a glance
- Originator UroCor
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 29 Jul 2002 Immunex acquired by and merged into Amgen
- 07 Nov 2000 Preclinical development for Cancer in USA (Unknown route)